Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 670,274
  • Shares Outstanding, K 256,810
  • Annual Sales, $ 403,140 K
  • Annual Income, $ -22,680 K
  • EBIT $ 60 M
  • EBITDA $ 63 M
  • 60-Month Beta 1.17
  • Price/Sales 1.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.76% (+15.22%)
  • Historical Volatility 79.75%
  • IV Percentile 54%
  • IV Rank 7.10%
  • IV High 719.03% on 04/09/25
  • IV Low 72.90% on 12/18/25
  • Expected Move (DTE 13) 0.31 (11.72%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 1,079
  • Volume Avg (30-Day) 2,141
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 88,090
  • Open Int (30-Day) 94,298
  • Expected Range 2.30 to 2.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $0.00
  • Low Estimate $-0.09
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +80.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +9.43%
on 03/13/26
3.27 -20.18%
on 03/10/26
-0.66 (-20.18%)
since 03/02/26
3-Month
2.38 +9.43%
on 03/13/26
4.18 -37.49%
on 01/08/26
-1.10 (-29.65%)
since 01/02/26
52-Week
0.69 +276.90%
on 05/15/25
4.18 -37.49%
on 01/08/26
+1.22 (+87.77%)
since 04/02/25

Most Recent Stories

More News
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

–  Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...

ESPR : 2.61 (unch)
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25 th Annual Needham Virtual Healthcare Conference...

ESPR : 2.61 (unch)
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

–  Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk...

ESPR : 2.61 (unch)
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE)...

ESPR : 2.61 (unch)
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia...

ESPR : 2.61 (unch)
Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Therapeutics: Q4 Earnings Snapshot

ESPR : 2.61 (unch)
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025...

ESPR : 2.61 (unch)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular...

ESPR : 2.61 (unch)
KKR : 91.23 (-0.14%)
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

–  Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular...

ESPR : 2.61 (unch)
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March...

ESPR : 2.61 (unch)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 2.80
2nd Resistance Point 2.73
1st Resistance Point 2.67
Last Price 2.61
1st Support Level 2.54
2nd Support Level 2.46
3rd Support Level 2.40

See More

52-Week High 4.18
Fibonacci 61.8% 2.84
Last Price 2.61
Fibonacci 50% 2.43
Fibonacci 38.2% 2.02
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.